Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan-based cefuroxime-containing regimen for penicillin-allergic patients with Helicobacter pylori infection
ChiCTR2600127085Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegoprazan, amoxicillin, cefuroxime, doxycycline and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: Treatment success rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tegoprazanamoxicillincefuroximedoxycyclinebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600127085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127085.